Riskpilot← Back to searchSign inGet full accessAllarity Therapeutics Denmark ApS
APSActiveCVR 38445928Venlighedsvej 1Manufacture of pharmaceutical preparations · NACE 2120Est. 2017— employees
Revenue 2024
DKK 33K
EBITDA margin
100.0%
Equity ratio
-61900.0%
Financial strength
Net profit 2024
DKK 174K
+114% vs 2023
| Revenue | DKK 33K | — |
| EBITDA | DKK 33K | — |
| Net profit | DKK 174K | +114% |
| Total assets | DKK 4K | -100% |
| Equity | DKK -2,5M | +7% |
| Employees | — | — |
Legal name
Allarity Therapeutics Denmark ApS
CVR number
38445928
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
13. februar 2017
Share capital
DKK 100.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af 1 direktør
Company purpose
Selskabets formål er at undersøge om et stof fra Big Pharma kan anvendes sammen med DRPTM.
Address
Venlighedsvej 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -2.169 | -1 | 0 | — | 33 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -2.169 | -1 | 0 | 0 | 33 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -2.169 | -1 | 0 | 0 | 33 |
| Net financials | -69 | -6 | -1.512 | -1.220 | 141 |
| Profit before tax | -2.238 | -7 | -1.512 | -1.220 | 174 |
| Tax | -593 | -7 | -59 | -0 | -0 |
| Net profit | -1.645 | 0 | -1.453 | -1.220 | 174 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 12.632 | 6.935 | 6.551 | 6.551 | 4 |
| Equity | 22 | 23 | -1.430 | -2.650 | -2.476 |
| Long-term debt | 0 | 6.423 | 7.551 | 8.771 | 0 |
| Short-term debt | 12.148 | 430 | 430 | 430 | 2.480 |
| Total debt | 12.148 | 6.853 | 7.981 | 9.201 | 2.480 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20202024
Equity ratio
-61900.0%
This company
38.2%
Market median
-162142% vs market
20202024
Return on equity
17400000.0%
This company
18.4%
Market median
+94565117% vs market
20202024
Net profit margin
527.3%
This company
8.1%
Market median
+6410% vs market
20202024
Asset turnover
8.25×
This company
1.12×
Market median
+637% vs market
20202024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JS Management | Management | 2025 |
SM Chief Executive Officer | Chief Executive Officer | 2023 |
| Former (6) | ||
TH Management | Management | 2017 – 2021 |
JE Management | Management | 2021 – 2022 |
AE Management | Management | 2024 – 2025 |
SR Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
JG Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
JY Management | Management | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Board of Directors | 2017 – 2018 | |
| Chairman | 2017 – 2018 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2021 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Allarity Therapeutics Denmark ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jeffrey Stuart Ervin | Management | 0 companies |
| Thomas Henrik Jensen | Management | 0 companies |
| Jens Erik Knudsen | Management | 0 companies |
| Alexander Epshinsky | Management | 0 companies |
| Stefano Roberto Carchedi | Chief Executive Officer | 0 companies |
| James G. Cullem | Chief Executive Officer | 0 companies |
| Joan Yvonne Brown | Management | 0 companies |
| Steen Meier Knudsen | Chief Executive Officer | 0 companies |
| Ulla Hald Buhl | Board of Directors | 0 companies |
| Peter Buhl | Chairman | 0 companies |